Advertisement

Author: Reuters

Gene therapy stocks plunge after poor trial data

(Reuters) – Shares of U.S. gene therapy companies sank on Thursday after drugs developed by two small firms failed to show promise in separate clinical trials, underscoring the challenges in an emerging, lucrative field of...

Read More

For latest news and updates
Email-id is invalid